https://doi.org/10.4081/aiua.2025.13820
A comparison of renal cell carcinoma with tumor thrombus across North America, Central/South America, and South Korea
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 9 June 2025
Purpose: With multi-institutional collaboration, the purpose of this study was to analyze geographical differences of renal cell carcinoma with tumor thrombus between patients in North America, Central/South America, and South Korea.
Materials and methods: Patients with renal cell carcinoma and a tumor thrombus who underwent nephrectomy plus thrombectomy were retrospectively analyzed. Patients were from North America, Central/South America, and South Korea. All comparisons were done based on the region where a patient had their surgery and follow-up. Chi-squared test, analysis of variance, Kaplan-Meier survival with log-rank test, and Cox regression analysis were used.
Results: A total of 478 patients were included, 212 from North America, 209 from Central/South America, and 57 from South Korea. Of note, thrombus level was different using the Neves classification system between regions (p<0.001), with a greater thrombus level in Central/South America. Surgical approach differed, with laparoscopic cases done most often in Central/South America and robotic in North America (p<0.001). Tumor grade was lowest in South Korea (p<0.001) and stage (p<0.001) greatest in Central/South America. Overall survival was greater in South Korea compared to Central/South America (p=0.026). Cancer-specific survival was greater in South Korea relative to North America and Central/South America (p=0.026).
Conclusions: Patients from North America, Central/South America, and South Korea diagnosed with renal cell carcinoma and tumor thrombus do not present the same and have different outcomes peri-/post-operatively. This includes important variables which have impacts on patient morbidity and mortality. Considering increased efforts on health equity in urology,
Downloads
Almatari AL, Sathe A, Wideman L, et al. Renal cell carcinoma with tumor thrombus: A review of relevant anatomy and surgical techniques for the general urologist. Urol Oncol 2023; 41:153-165. DOI: https://doi.org/10.1016/j.urolonc.2022.11.021
Tilki D, Hu B, Nguyen HG, et al. Impact of synchronous metastasis distribution on cancer specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy. J Urol. 2015;193:436-42. DOI: https://doi.org/10.1016/j.juro.2014.07.087
Tang Q, Song Y, Li X, et al. Prognostic outcomes and risk factors for patients with renal cell carcinoma and venous tumor thrombus after radical nephrectomy and thrombectomy: The prognostic significance of venous tumor thrombus level. Biomed Res Int. 2015;2015:163423. DOI: https://doi.org/10.1155/2015/163423
Anastos H, Martini A, Waingankar N, et al. Black race may be associated with worse overall survival in renal cell carcinoma patients. Urol. Oncol. 2020; 38:938.e9-938.e17. DOI: https://doi.org/10.1016/j.urolonc.2020.08.034
Gupta A, Roy AM. Racial and Ethnic Disparities in Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Receiving Immunotherapy. Clin Genitourin Cancer. 2024; 22:102104. DOI: https://doi.org/10.1016/j.clgc.2024.102104
Cirillo L, Innocenti S, Becherucci F. Global epidemiology of kidney cancer. Nephrol Dial Transplant. 2024; 39:920-928. DOI: https://doi.org/10.1093/ndt/gfae036
Bukavina L, Bensalah K, Bray F, et al. Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur Urol. 2022; 82:529-542. DOI: https://doi.org/10.1016/j.eururo.2022.08.019
Capitanio U, Bensalah K, Bex A, et al. Epidemiology of Renal Cell Carcinoma. Eur Urol. 2019; 75:74-84. DOI: https://doi.org/10.1016/j.eururo.2018.08.036
Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020; 11:79-87. DOI: https://doi.org/10.14740/wjon1279
Fay AP, McKay RR, Lin X, et al. Impact of geographic regions on overall survival in patients with metastatic renal cell carcinoma: Results from an international clinical trials database. J Glob Oncol. 2018; 2018:1-14. DOI: https://doi.org/10.1200/JGO.17.00119
Neves RJ, Zincke H. Surgical Treatment of Renal Cancer with Vena Cava Extension. Br J Urol. 1987; 59:390-5. DOI: https://doi.org/10.1111/j.1464-410X.1987.tb04832.x
Brierley J.D., Gospodarowicz M.K., Wittekind C. TNM Classification of Malignant Tumours, 8th edition. Union for International Cancer Control. https://www. uicc.org/resources/tnm-classification-malignant-tumours-8th-edition
Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37:1490-504. DOI: https://doi.org/10.1097/PAS.0b013e318299f0fb
Goebell PJ, Müller L, Hübner A, et al. Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment—Analyses from the German clinical RCC-Registry. Urol Oncol 2018; 36:433-472. DOI: https://doi.org/10.1016/j.urolonc.2018.07.007
Dursun F, Patel R, Hui D, et al. The Latinx Disparity in Surgery for Kidney Cancer: Data from The South Texas Region. Kidney Cancer J. 2022; 20:6-13. DOI: https://doi.org/10.52733/KCJ20n1-a1
Xu Y, Qi Y, Zhang J, et al. The impact of smoking on survival in renal cell carcinoma: A systematic review and meta-analysis. Tumor Biol. 2014; 35:6633-40. DOI: https://doi.org/10.1007/s13277-014-1862-8
Kaptein FHJ, van der Hulle T, Braken SJE, et al. Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma. JACC CardioOncol. 2022; 4:522-531. DOI: https://doi.org/10.1016/j.jaccao.2022.07.011
Soares A, Monteiro FSM, da Trindade KM, et al. Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update. J Cancer Res Clin Oncol. 2024;150:183. DOI: https://doi.org/10.1007/s00432-024-05663-z
Woodruff DY, Van Veldhuizen P, Muehlebach G, et al. The perioperative management of an inferior vena caval tumor thrombus in patients with renal cell carcinoma. Urol. Oncol. 2013; 31:517-21. DOI: https://doi.org/10.1016/j.urolonc.2011.03.006
Garg H, Psutka SP, Hakimi AA, et al. A Decade of Robotic-Assisted Radical Nephrectomy with Inferior Vena Cava Thrombectomy: A Systematic Review and Meta-Analysis of Perioperative Outcomes. J Urol. 2022; 208:542-560. DOI: https://doi.org/10.1097/JU.0000000000002829
Sun Y, De Castro Abreu AL, Gill IS. Robotic inferior vena cava thrombus surgery: Novel strategies. Curr Opin Urol. 2014; 24:140-7. DOI: https://doi.org/10.1097/MOU.0000000000000033
Pandey J, Syed W. Renal Cancer. Treasure Island, FL:StatPearls Publishing; 2024.
Tian J, Zeng X, Guan W, et al. Prognostic indicators for survival in renal cell carcinoma with venous thrombus and development of predictive nomograms. Transl Androl Urol. 2022; 11:1374-1388. DOI: https://doi.org/10.21037/tau-22-128
Yang B, Xia H, Xu C, et al. Impact of sarcomatoid differentiation and rhabdoid differentiation on prognosis for renal cell carcinoma with vena caval tumour thrombus treated surgically. BMC Urol. 2020; 20:14. DOI: https://doi.org/10.1186/s12894-020-0584-z
Tilki D, Chandrasekar T, Capitanio U, et al. Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Urol Oncol. 2018; 36:79.e11-79.e17. DOI: https://doi.org/10.1016/j.urolonc.2017.10.008
Smith MR, Mehra M, Nair S, et al. Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2020; 18:e180-e189. DOI: https://doi.org/10.1016/j.clgc.2019.10.030
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.